INTRODUCTION {#s1}
============

The long-term survival of early-stage breast cancer patients is equivalent to either breast-conserving surgery (BCS) plus radiation therapy (RT) or modified radical mastectomy, as demonstrated in several prospective randomized controlled trials (RCTs) \[[@R1]--[@R6]\]. However, participants in RCT sare highly selected and may not represent the general population. Although RCT scan provide the least biased estimates for treatment comparisons, their results may not correspond to actual clinical situations \[[@R7]\]. In daily routine practice, physicians make decisions based on many uncontrolled factors and apply the results of RCTs to a broader range of patients. Therefore, observational studies are relied on to provide additional information regarding the comparative effectiveness of different treatments in the general population \[[@R7]\]. Abdulkarim, *et al* reported that in T1--2N0M0 triple-negative (TN) patients, modified radical mastectomy without RT significantly increased the risk of local failure compared with BCS+RT \[[@R8]\]. This interesting finding was also observed in Adkins\' study \[[@R9]\] but not in that by Zumsteg \[[@R10]\]. In addition, studies using data from national cancer registries \[[@R11]--[@R13]\] reported similar findings: that BCS+RT was associated with improved survival compared with mastectomy alone or mastectomy with RT.

In general, the findings from observational studies suffer from selection bias. For example, it is possible that patients who receive BCS+RT are more likely to have fewer comorbidities, which contributes to its superior survival rates. Information about comorbidities was usually unavailable in previous studies \[[@R11], [@R13]\]. Here, we retrospectively compared the long-term overall survival (OS) between BCS and mastectomy using the National Cancer Database (NCDB). The NCDB is a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society \[[@R7]\]. It includes more than 1,500 commission-accredited cancer programs in the United States and contains detailed tumor pathology information. Additionally, the insurance type, comorbidities (Charlson-Deyo score) and days of inpatient stay were collected, which enable us to identify patients with low/high comorbidities. We hypothesized that by using a large national cohort of breast cancer patients, this analysis would provide additional evidence in the relative effectiveness of the association between local therapy (BCS *vs*. mastectomy) and clinical outcomes. To minimize the influence of "confounding by indications", we planned to perform subgroup analyses by comorbidities or age. We hypothesized that in patients with no/few comorbidities, or younger age, there would be no differences of OS between BCS and mastectomy.

RESULTS {#s2}
=======

We identified 160,880 patients who fit the inclusion and exclusion criteria. The median age was 60 years old, and 59.1%, 34.1% and 6.0% of the patients had AJCC Stage I, II and III disease, respectively. A total of 126,569(78.7%), 26,130(16.2%) and 8,181(5.1%) patients had received BCS+RT, mastectomy alone and mastectomy+RT, respectively. As shown in Table [1](#T1){ref-type="table"}, patients in the BCS group were more likely to have private insurance, fewer comorbid diseases (CD scor*e* = 0), lower tumor burden (smaller tumor and/or negative nodes), and fewer hormone receptor-positive diseases. Additionally, BCS patients were wealthier and had a higher education level, and the majority of women (83.9%) received surgery at clinics without inpatient stays after surgery.

###### Clinicopathological features of included patients

                                                 Surgery   *P*                                   
  ---------------------------------------------- --------- ------ -------- ------ ------- ------ ---------
  **Facility Type**                                                                              
   1: Community Cancer Program                   13,675    10.8   3,480    13.3   963     11.8   \<0.001
   2: Comprehensive Community Cancer Program     76,163    60.2   16,039   61.4   4,850   59.3   
   3: Academic/Research Program                  36,500    28.8   6,582    25.2   2,358   28.8   
   9: Other Specified Types Of Cancer Programs   231       0.2    29       0.1    10      0.1    
  **Primary Payor**                                                                              
   0: Not Insured                                2,048     1.6    632      2.4    307     3.8    \<0.001
   1: Private Insurance                          78,123    61.7   11,151   42.7   4,651   56.9   
   2: Medicaid                                   6,573     5.2    1,963    7.5    898     11.0   
   3: Medicare                                   38,745    30.6   12,173   46.6   2,253   27.5   
   4: Other Government                           1,080     0.9    211      0.8    72      0.9    
  **City Type**                                                                                  
   Metropolitan                                  109,539   86.5   21,269   81.4   6,807   83.2   \<0.001
   Urban                                         15,167    12.0   4,190    16.0   1,223   14.9   
   Rural                                         1,863     1.5    671      2.6    151     1.8    
  **Distance**                                                                                   
   \<10_Miles                                    72,677    57.4   14,326   54.8   4,447   54.4   \<0.001
   \>10_Miles                                    53,892    42.6   11,804   45.2   3,734   45.6   
  **Median Income Quartiles 2008--2012**                                                         
   \<\$47999                                     43,364    34.3   11,675   44.7   3,520   43.0   \<0.001
   \$48000+                                      83,205    65.7   14,455   55.3   4,661   57.0   
  **Percent No High School Degree 2008--2012**                                                   
   \>=13%                                        44,585    35.2   11,813   45.2   3,635   44.4   \<0.001
   \<13%                                         81,984    64.8   14,317   54.8   4,546   55.6   
  **Age Group**                                                                                  
   \<=60                                         68,492    54.1   10,463   40.0   5,008   61.2   \<0.001
   \>60                                          58,077    45.9   15,667   60.0   3,173   38.8   
  **Race**                                                                                       
   White                                         109,050   86.2   21,731   83.2   6,525   79.8   \<0.001
   African American                              12,782    10.1   2,946    11.3   1,173   14.3   
   Others                                        4,737     3.7    1,453    5.6    483     5.9    
  **Charlson-Deyo Score**                                                                        
   0                                             109,623   86.6   20,216   77.4   6,785   82.9   \<0.001
   1                                             14,559    11.5   4,662    17.8   1,129   13.8   
   2                                             2,387     1.9    1,252    4.8    267     3.3    
  **T-Stage**                                                                                    
   T1                                            98,660    77.9   15,001   57.4   2,841   34.7   \<0.001
   T2                                            27,909    22.1   11,129   42.6   5,340   65.3   
  **N-Stage**                                                                                    
   N0                                            98,236    77.6   17,756   68.0   1,236   15.1   \<0.001
   N1                                            23,480    18.6   7,114    27.2   3,276   40.0   
   N2                                            3,776     3.0    938      3.6    2,622   32.0   
   N3                                            1,077     0.9    322      1.2    1,047   12.8   
  **Stage**                                                                                      
   I                                             82,728    65.4   11,725   44.9   689     8.4    \<0.001
   II                                            39,022    30.8   13,148   50.3   3,845   47.0   
   III                                           4,819     3.8    1,257    4.8    3,647   44.6   
  **Grade**                                                                                      
   I                                             30,644    24.2   4,213    16.1   744     9.1    \<0.001
   II                                            54,309    42.9   11,114   42.5   3,180   38.9   
   III                                           41,616    32.9   10,803   41.3   4,257   52.0   
  **Estrogen Receptor**                                                                          
   Negative                                      24,873    19.7   7,218    27.6   2,205   27.0   \<0.001
   Positive                                      101,696   80.3   18,912   72.4   5,976   73.0   
  **Progesterone Receptor**                                                                      
   Negative                                      36,308    28.7   9,812    37.6   3,047   37.2   \<0.001
   Positive                                      90,261    71.3   16,318   62.4   5,134   62.8   
  **Laterality**                                                                                 
   Right                                         62,677    49.5   12,643   48.4   4,018   49.1   \<0.001
   Left                                          63,892    50.5   13,487   51.6   4,163   50.9   
  **Primary Site**                                                                               
   Central                                       4,554     3.6    1,907    7.3    550     6.7    \<0.001
   LIQ                                           8,133     6.4    1,669    6.4    415     5.1    
   LOQ                                           9,714     7.7    2,063    7.9    694     8.5    
   UIQ                                           308       0.2    162      0.6    38      0.5    
   UOQ                                           35,575    28.1   8,962    34.3   2,977   36.4   
   Nipple                                        17,925    14.2   3,014    11.5   650     7.9    
   Others                                        50,360    39.8   8,353    32.0   2,857   34.9   
  **Lymphovascular Invasion**                                                                    
   Negative                                      37,013    29.2   6,293    24.1   1,286   15.7   \<0.001
   Positive                                      7,562     6.0    1,790    6.9    1,394   17.0   
   Unknown                                       81,994    64.8   18,047   69.1   5,501   67.2   
  **Chemotherapy**                                                                               
   No                                            68,989    54.5   14,128   54.1   1,156   14.1   \<0.001
   Yes                                           57,580    45.5   12,002   45.9   7,025   85.9   
  **Days Of Inpatient Stay**                                                                     
   0                                             106,199   83.9   5,537    21.2   2,126   26.0   \<0.001
   1                                             14,138    11.2   13,287   50.8   3,965   48.5   
   \>1                                           6,232     4.9    7,306    28.0   2,090   25.5   

BCS, breast-conserving surgery; RT, Radiation therapy; LIQ, lower-inner quadrant; LOQ, lower-outer quadrant; UIQ, Upper-inner quadrant; UOQ, Upper-outer quadrant; NS, non-significant;

Survival benefit of BCS over mastectomy in the entire study cohort {#s2_1}
------------------------------------------------------------------

With a median follow-up of 43.4 months, the respective 5-year and 8-year OS values were 93.2% and 86.5% in the BCS+RT group, 83.5% and 72.3% in the mastectomy-alone group, and 83.0% and 70.4% in the mastectomy+RT group, respectively (log-rank test; *P* \< 0.001). Univariate ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) and multivariate analyses ([Supplementary Table 2A](#SD3){ref-type="supplementary-material"}) revealed that mastectomy (alone or with RT) was significantly associated with a lower 5-year and 8-year overall survival in patients with N0, N1 and N2--3 disease compared with BCS+RT (Figure [1A--1C](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

![Kaplan-Meier survival analysis of the entire population A--C. and in patients with "Less/No comorbid conditions" D--F. Analysis were performed separately in N0 (A, D), N1 (B, E) and N2--3 (C, F) patients](oncotarget-06-40127-g001){#F1}

###### Survival benefit of BCS+RT over mastectomy+/−RT varied across patients with different comorbid diseases or age

  Features                                                                           *N*      Overall survival %   Cox-regerssion[\*\*](#tfn_002){ref-type="table-fn"}   Post-mastectomy OS benefit[\*](#tfn_001){ref-type="table-fn"}                                                            
  ---------------------------------------------------------------------------------- -------- -------------------- ----------------------------------------------------- --------------------------------------------------------------- --------- ------------------ --------- -------- -------- --
  **All patients[\#](#tfn_003){ref-type="table-fn"}**                                                                                                                                                                                                                                             
  N0                                                                                 BCS+RT   98,236               94.2%                                                 88.0%                                                           1                            1                           
  Mastectomy_alone                                                                   17,756   86.5%                75.8%                                                 2.39(2.27--2.52)                                                \<0.001   1.40(1.31--1.50)   \<0.001   2.34%    1.94%    
  Mastectomy+RT                                                                      1,236    88.9%                77.8%                                                 1.96(1.64--2.35)                                                \<0.001   1.52(1.26--1.83)   0.001                       
  N1                                                                                 BCS+RT   23,480               91.8%                                                 83.8%                                                           1                            1                           
  Mastectomy_alone                                                                   7,114    81.0%                68.8%                                                 2.44(2.26--2.63)                                                \<0.001   1.44(1.31--1.58)   \<0.001   5.71%    7.25%    
  Mastectomy+RT                                                                      3,276    86.7%                76.1%                                                 1.64(1.46--1.85)                                                \<0.001   1.33(1.17--1.51)   \<0.001                     
  N2-3                                                                               BCS+RT   4,853                82.9%                                                 73.3%                                                           1                            1                           
  Mastectomy_alone                                                                   1,260    57.1%                46.6%                                                 3.01(2.67--3.39)                                                \<0.001   1.64(1.42--1.88)   \<0.001   21.00%   16.87%   
  Mastectomy+RT                                                                      3,669    78.1%                63.4%                                                 1.34(1.20--1.49)                                                \<0.001   1.12(1.00--1.26)   0.052                       
  **Patiens with less/no comorbid diseases [\#\#](#tfn_004){ref-type="table-fn"}**                                                                                                                                                                                                                
  N0                                                                                 BCS+RT   81,893               94.9%                                                 89.3%                                                           1                            1                           
  Mastectomy_alone                                                                   10,550   89.9%                81.5%                                                 2.01(1.86--2.17)                                                \<0.001   1.38(1.28--1.49)   \<0.001   0.39%    −2.62%   
  Mastectomy+RT                                                                      900      90.3%                78.9%                                                 2.00(1.60--2.52)                                                \<0.001   1.67(1.33--2.10)   \<0.001                     
  N1                                                                                 BCS+RT   18,742               92.6%                                                 85.5%                                                           1                            1                           
  Mastectomy_alone                                                                   3,844    85.3%                73.6%                                                 2.07(1.86--2.31)                                                \<0.001   1.41(1.26--1.58)   \<0.001   2.95%    4.80%    
  Mastectomy+RT                                                                      2,079    88.2%                78.4%                                                 1.66(1.42--1.93)                                                \<0.001   1.41(1.21--1.65)   \<0.001                     
  N2-3                                                                               BCS+RT   3,775                83.6%                                                 74.9%                                                           1                            1                           
  Mastectomy_alone                                                                   653      64.8%                53.5%                                                 2.49(2.11--2.94)                                                \<0.001   1.52(1.27--1.82)   \<0.001   15.92%   13.03%   
  Mastectomy+RT                                                                      2,206    80.7%                66.6%                                                 1.22(1.07--1.40)                                                0.003     1.12(0.97--1.28)   0.126                       
  **Patiens with age\<=50 [\#\#\#](#tfn_005){ref-type="table-fn"}**                                                                                                                                                                                                                               
  N0                                                                                 BCS+RT   22,638               96.7%                                                 94.0%                                                           1                            1                           
  Mastectomy_alone                                                                   3,106    93.7%                89.3%                                                 2.01(1.70--2.38)                                                \<0.001   1.42(1.16--1.74)   0.001     −0.76%   −4.55%   
  Mastectomy+RT                                                                      449      92.9%                84.7%                                                 2.31(1.59--3.36)                                                \<0.001   1.70(1.15--2.50)   0.007                       
  N1                                                                                 BCS+RT   6,857                93.6%                                                 88.9%                                                           1                            1                           
  Mastectomy_alone                                                                   1,450    90.2%                82.8%                                                 1.49(1.21--1.83)                                                \<0.001   1.13(0.90--1.43)   0.292     1.38%    −1.50%   
  Mastectomy+RT                                                                      1,242    91.5%                81.3%                                                 1.50(1.20--1.88)                                                0.001     1.23(0.96--1.57)   0.101                       
  N2-3                                                                               BCS+RT   1,615                85.2%                                                 77.7%                                                           1                            1                           
  Mastectomy_alone                                                                   247      73.5%                68.1%                                                 1.81(1.34--2.43)                                                \<0.001   1.20(0.87--1.67)   0.27      11.28%   7.42%    
  Mastectomy+RT                                                                      1,097    84.8%                75.5%                                                 1.06(0.86--1.31)                                                0.587     0.92(0.72--1.17)   0.514                       
  **Patiens with age\>50 [\#\#\#](#tfn_005){ref-type="table-fn"}**                                                                                                                                                                                                                                
  N0                                                                                 BCS+RT   75,598               93.4%                                                 85.8%                                                           1                            1                           
  Mastectomy_alone                                                                   14,650   84.9%                72.5%                                                 2.34(2.21--2.47)                                                \<0.001   1.40(1.31--1.51)   \<0.001   1.60%    0.34%    
  Mastectomy+RT                                                                      787      86.5%                72.9%                                                 2.11(1.71--2.60)                                                \<0.001   1.47(1.19--1.82)   0.004                       
  N1                                                                                 BCS+RT   16,623               90.9%                                                 81.4%                                                           1                            1                           
  Mastectomy_alone                                                                   5,664    78.4%                64.8%                                                 2.54(2.33--2.75)                                                \<0.001   1.51(1.37--1.67)   \<0.001   5.05%    7.92%    
  Mastectomy+RT                                                                      2,034    83.5%                72.8%                                                 1.79(1.56--2.05)                                                \<0.001   1.38(1.19--1.60)   \<0.001                     
  N2-3                                                                               BCS+RT   3,238                81.7%                                                 70.7%                                                           1                            1                           
  Mastectomy_alone                                                                   1,013    52.8%                40.1%                                                 3.23(2.83--3.68)                                                \<0.001   1.86(1.60--2.18)   \<0.001   22.29%   17.93%   
  Mastectomy+RT                                                                      2,572    75.1%                58.0%                                                 1.43(1.26--1.61)                                                \<0.001   1.22(1.06--1.40)   0.005                       

Post-mastectomy RT benefit=cumulative survival rate of mastectomy+RT - cumulative survival rate of mastectomy alone

For multivariable anslysis, facility type, primary payor, city type, distance to hospital, median income, percentage of no high school degree, age, race, Charlson-Deyo score, T-stage, N-stage, Grade, estrogen receptor, progesterone receptor, primary site, lymphovascular invasion, radiation therapy, chemotherapy, days of inpatient stay and surgery were incorported into the full model. In subgroup analysis, the respective variables that had been used for stratification were excluded as indicated.

N-stage were excluded from the full model of multivariate analysis.

N-stage, days of inpatient stay and Charlson-Deyo score were excluded from the full model of multivariate analysis

N-stage and age were excluded from the full model of multivariate analysis

BCS, breast-conserving surgery; RT, radiation therapy; HR, hazard ratio; CI, confidence interval;

Survival benefit of BCS over mastectomy in patients with fewer/no comorbidities {#s2_2}
-------------------------------------------------------------------------------

A total of 124,642 patients with a CD score of 0 and days of inpatient stay ≤1 were considered to have fewer/no comorbid diseases and were included in this analysis (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). In N0 patients, BCS+RT (vs. mastectomy alone) increased the 5-year and 8-year OS by 5.0% and 7.8%, respectively. After adjustment, mastectomy alone (*vs*. BCS+RT) was significantly associated with a lower OS (HR 1.38, 95% CI 1.28--1.49) ([Supplementary Table 2B](#SD4){ref-type="supplementary-material"}). In N1 patients, mastectomy (alone or with RT) was significantly correlated with a lower OS (Table [2](#T2){ref-type="table"}, Figure [2B](#F2){ref-type="fig"}). However, among N2--3 patients, mastectomy+RT (*vs*. BCS+RT) was no longer associated with a lower OS after adjustment (HR 1.12, 95% CI 0.97--1.28). The 5-year OS benefit of BCS+RT over mastectomy+RT was less than 5% (Figure [2A](#F2){ref-type="fig"}).

![A. Improvement of OS in N0, N2--3 patients. The benefit of 5-year and 8-year OS was calculated by comparing BCS+RT with mastectomy alone in N0 patients, and with mastectomy+RT in N2--3 patients\
**B.** Improvement of OS in N1 patients. The survival benefit of BCS+RT over mastectomy alone or with RT was shown as indicated. BCS, breast-conserving surgery; M, Mastectomy; RT, radiation therapy.](oncotarget-06-40127-g002){#F2}

Survival benefit of BCS over mastectomy varied by age {#s2_3}
-----------------------------------------------------

Among patients aged 50 or younger, the 5-year and 8-year survival benefit of BCS+RT (*vs*. mastectomy alone or with RT) was significantly lower than that of patients with age ≥50yrs (Figure [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} [Supplementary Table 2C](#SD5){ref-type="supplementary-material"}). BCS+RT over mastectomy alone was statistically significant (HR 1.42, 95% CI 1.16--1.74) but not clinically significant (5-year: 2.9%; 8-year: 4.8%) in N0 patients. In N1 and N2--3 patients, BCS+RT over mastectomy+RT was not significantly correlated with an improved OS (Table [2](#T2){ref-type="table"} [Supplementary Table 2C](#SD5){ref-type="supplementary-material"}). The survival benefit of BCS+RT *vs*. mastectomy (alone or with RT) in patients older than 50 were similar to the entire population (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} [Supplementary table 2d](#SD6){ref-type="supplementary-material"}).

![Kaplan-Meier survival analysis of the patients with age ≤50 A--C. and age \> 50 D--F. respectively\
Analysis was performed separately in N0 (A, D), N1 (B, E) and N2--3 (C, F) patients](oncotarget-06-40127-g003){#F3}

Propensity score analysis of OS {#s2_4}
-------------------------------

We used propensity scores to create strata in which the possibility of having a specific treatment (BCS+RT *vs*. mastectomy ± RT) was similar for all patients in the same strata, regardless of their actual received treatment. Using a Cox-regression model stratified by propensity score quintile, we found that mastectomy alone (*vs*. BCS+RT) was associated with a worse OS in N0 (HR 1.75, 95% CI 1.66--1.85) and N1 patients(HR 1.73, 95% CI 1.60--1.88). Mastectomy+RT *vs*. BCS+RT was correlated with a lower OS in N1 patients (HR 1.24, 95% CI 1.10--1.39), but not in N2--3 patients (HR 1.09, 95% CI 0.98--1.21).

Survival benefit of post-mastectomy radiotherapy (PMRT) {#s2_5}
-------------------------------------------------------

In the entire cohort, the 5-year OS benefit of PMRT (mastectomy+RT *vs.* mastectomy alone) was 2.3%, 5.7% and 21.0% in N0, N1 and N2--3 patients, respectively (Table [2](#T2){ref-type="table"}, Figure [1A-1C](#F1){ref-type="fig"}). After the exclusion of patients with comorbid conditions, the respective OS benefit of PMRT was less than 5% in N0 and N1 patients, and 15.9% in N2--3 patients (Table [2](#T2){ref-type="table"}, Figure [1D-1F](#F1){ref-type="fig"}). Among patients aged 50 or younger, there was no benefit of PMRT in N0 and N1 patients, while in N2--3 patients, the OS benefit of PMRT was 11.3% (Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"}).

DISCUSSION {#s3}
==========

Recent studies of the comparative effectiveness of BCS+RT *vs*. mastectomy {#s3_1}
--------------------------------------------------------------------------

Randomized controlled trials had demonstrated that BCS has an equivalent long-term survival to mastectomy \[[@R3], [@R4], [@R6], [@R14]--[@R18]\] in early-stage breast cancer patients. The comparative effectiveness of BCS+RT *vs*. mastectomy in non-clinical-trial population has been investigated in administrative, observational database. Hwang, *et al* \[[@R13]\] identified 112,154 stage I and II breast cancer patients from the large population-based prospective California Cancer Registry. The authors observed that women who underwent BCS+RT had improved breast cancer specific survival(BCSS) and OS compared with those treated by mastectomy, and the survival benefit of BCS+RT was greater among "≥50yrs & HR+" women. Brooks, *et al* \[[@R19]\] used the instrumental variable method to study the SEER-Medicare database and reported that higher mastectomy rates were associated with reduced survival. Other studies using data from national cancer registries in Norway \[[@R12]\], Canada \[[@R20]\] and the US \[[@R11], [@R21]\] reported similar findings (Table [3](#T3){ref-type="table"}).

###### Comparative effectiveness studies comparing clinical outcomes of patients receiving BCS and mastectomy in non-clinical trial population

  Article                   Data source                        Years of diagnosis   Inclusion criteria                           Median follow-up (months)   Surgery group   Sample size   Outcomes                                       
  ------------------------- ---------------------------------- -------------------- -------------------------------------------- --------------------------- --------------- ------------- ---------- --------- ------------------------- ------------
  Hwang et al.              California Cancer Registry, US     1990--2004           T1/T2, Stage I-II,                           110.6                       BCS+RT          61,777        CSS:89.3   N/A       N/A                       N/A
  Mastectomy alone          50,383                             OS:94.4                                                                                                                                                                    
  Agarwal et al             SEER, US                           1998--2008           Tumor size\<4cm or positive lymph nodes\<3   N/A                         BCS+RT          92,671        CSS:97     CSS:94    CSS: 3--7                 CSS: 4--11
  Mastectomy alone          34,999                             CSS:94               CSS:90                                                                                                                                                
  Mastectomy+RT             4,479                              CSS:90               CSS:83                                                                                                                                                
  Zumsteg et al.            Memorial Sloan-Kettering           1999--2008           T1-T2N0, TNBC                                76.4                        BCS+RT          448           LRFS:95    N/A       LRFS: 1.2                 N/A
  Mastectomy alone          198                                LRFS:94              DMFS:                                        N/A                                                                                                      
  Fisher et al.             Alberta Cancer Registry, Canada    2002--2010           Stage I-III                                  50.4                        BCS alone       805           OS:74      N/A       OS:11CSS (Stage I):98.2   N/A
  BCS+RT                    5,722                              OS:94                                                                                                                                                                      
  Mastectomy+/−RT           8,412                              OS:83                                                                                                                                                                      
  Hartmann-Johnsen et al.   Cancer Registry of Norway          1998--2008           T1--2N0--1M0                                 N/A                         BCS+RT          8,065         CSS:97     N/A       CSS: 9 OS: 15             N/A
  Mastectomy+/−RT           4,950                              CSS:88                                                                                                                                                                     
  Abdulkarim et al.         Alberta Cancer Registry, Canada    1998--2008           T1-T2N0, TNBC                                86.4                        BCS+RT          319           LRFS:94    N/A       LRFS:7--9 OS:5--19        N/A
  Mastectomy alone          287                                LRFS:85                                                                                                                                                                    
  Mastectomy+RT             162                                LRFS:87                                                                                                                                                                    
  Adkins et al.             M. D. Anderson Cancer Center, US   1980--2007           Stage I-III, TNBC                            62                          BCS+/−RT        651           LRFS:76    N/A       LRFS: 5 DMFS:14           N/A
  Mastectomy+/−RT           674                                LRFS:71                                                                                                                                                                    
  Onitilo et al.            Marshfield Clinic, US              1994--2012           Stage 0-IV                                   67                          BCS+/−RT        3,340         OS:90.5    OS:78.4   OS: 6.3                   N/A
  Mastectomy+/−RT           1,995                              OS:84.2              OS:62.8                                                                                                                                               

Five-year or ten-year differences were calculated as the survival rate of BCS - survival rate of mastectomy.

BCS, breast-conserving surgery; RT, radiotherapy, LRR, local-recurrence-free survival; DMFS, distant-metastasis-free survival; OS, overall survival; CSS, cancer-specific survival; N/A, not available; TNBC, triple negative breast cancer; SEER, Surveillance, epidemiology and end results.

Fisher *et al* \[[@R20]\]. used data from Alberta Cancer Registry (Canada) and showed that the survival benefit of BCS+RT *vs*. mastectomy was less significant in stage I patients, than in stage II or III patients. The underlying reason may due to the low risk of relapse events in stage I patients, rendering the survival advantages of BCS+RT less likely to be noted. However, there were two limitations of their study: 1) They did not distinguish patients who received PMRT from those who did not. Additionally, they stratified the analysis by cancer stage, rather than N-stage. Thus, in the stage II strata that contained both node-negative and node-positive patients, the comparison of BCS *vs*. mastectomy was significantly confounded by the unknown PMRT status. 2) The proportion of patients with non-standard treatment (e.g. PMRT in N0 patients after mastectomy, or no PMRT in N2--3 patients after mastectomy) in their mastectomy group was unknown. Therefore, the accuracy and generalizability of their results were influenced.

In our study, we stratified the survival analysis by N-stage. We compared BCS+RT *vs*. mastectomy alone, BCS+RT *vs*. mastectomy alone *vs*. mastectomy+RT, BCS+RT *vs*. mastectomy+RT in N0, N1 and N2 patients, respectively. We believe that our design is clearer in purpose and more informative for clinical practices. Our study showed that in N0 patients that PMRT is not recommended, BCS+RT had better OS than mastectomy alone; whereas in N2--3 patients that PMRT is routinely performed, BCS+RT has equivalent OS to mastectomy+RT after adjustment (Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). These results suggested the importance of RT in the comparison of BCS and mastectomy using administrative database.

The impact of comorbid conditions and age {#s3_2}
-----------------------------------------

Confounding by indication is the major limitation for most retrospective studies. Specifically, patients with fewer comorbid conditions are more likely to receive BCS+RT and these patients are more likely to have better OS than those with many comorbidites. Land. *et al* \[[@R22]\] determined that patients with more comorbid conditions were more likely to die from breast cancer as well as other causes, using data from the Danish Breast Cancer Cooperative Group Registry. A study by Hwang et al \[[@R13]\] using the California Cancer Registry database showed that patients who received BCS+RT were less likely to die from cardiovascular disease, or chronic lower respiratory diseases. They inferred that mastectomy patients were more likely to have comorbid diseases, which may have influenced the surgical decision. Hence, we performed subgroup analysis by excluding patients with severe comorbidities. In the NCDB, the Charlson-Deyo (CD) score has been used to describe comorbid conditions. We defined patients with CD score = 0 (no comorbid conditions) and days of inpatient stay ≤1 as "low/no comorbidity" patients. In this subgroup of women, the 5-year OS benefit of BCS+RT was 5.0% in N0 patients (*vs.* mastectomy alone), and 2.9% in N2--3 patients (*vs*. mastectomy+RT). Compared with the results derived from our entire study population, the survival benefit of BCS+RT over mastectomy (alone or with RT) was decreased, suggesting that the significant survival benefit of BCS+RT in previous studies might be partially due to comorbid conditions. Subgroup analysis in patients with comorbidities was not performed, because the effect of "confounding by indication" may be more significant in these patients.

Survival analysis was also stratified by age. As shown in Table [2](#T2){ref-type="table"} and Figure [3](#F3){ref-type="fig"}, the 5-year and 8-year OS benefit of BCS+RT was less than 5% in patients aged 50 or younger, regardless of nodal status. The survival advantages of BCS+RT in patients older than 50 were similar to the entire population. Our result is consistent with previous studies. A population-based study by Cao *et al* \[[@R23]\] found that 965 patients aged 20 to 39 years with breast cancer treated from 1989 to 2003 showed no difference in the 15-year rates of BCSS. Similar results were observed in other studies \[[@R24], [@R25]\]. The findings from these studies, together with ours, reveal the oncological safety of BCS+RT, particularly in young patients.

Benefit of less extensive surgery: is it possible? {#s3_3}
--------------------------------------------------

More extensive surgery may theoretically lead to better or at least equivalent outcomes as less extensive surgery in cancer treatment. Is it possible that the opposite may be true? Studies in animal models have suggested that the surgical trauma of normal tissue promotes the implantation or growth of circulating tumor cells \[[@R26]--[@R29]\]. Thus, with mastectomy, would a larger wound produce more cytokines to activate the distant dormant tumor cells? There is evidence from clinical studies indicating such a possibility. A randomized controlled trial published in *Lancet* \[[@R30]\] compared the efficacy of laparoscopy-assisted colectomy and open colectomy for the treatment of non-metastatic colon cancer in terms of tumor relapse and CSS. With lesser surgical treatment, laparoscopy-assisted colectomy had a significantly higher CSS. Further studies of these hypothesis and exploration of the underlying mechanisms are needed.

Benefit of PMRT {#s3_4}
---------------

The benefit of PMRT in patients with N1 disease is controversial. A subgroup analysis of DBCG 82 randomized trials \[[@R31]\] suggested a similar OS benefit of RT in patients with N1 and N2--3 disease. Likewise, an EBCTCG meta-analysis using individual data from 22 trials \[[@R32], [@R33]\] revealed that PMRT reduced the rate of mortality in breast cancer patients, which was independent of the number of lymph nodes involved. The National Comprehensive Cancer Network (NCCN) guidelines \[[@R34]\] also recommend strong consideration of PMRT in N1 patients. However, our study demonstrated that PMRT was associated with an improved 5-year OS in N2--3 patients rather than N0 or N1 patients (Table [2](#T2){ref-type="table"}). Our study was not the first to question the need for PMRT in N1 patients. He, *et al* \[[@R35]\] reported that, in patients with T1--2 and N1 diseases, the survival benefit of PMRT was present only in high-risk patients. Huo, *et al* \[[@R36]\]analyzed 93,793 and 36,299 T1--2N1 breast cancer patients in the NCDB and SEER database and showed that PMRT improved OS among patients with 3 positive nodes or 2 positive nodes with tumors 2--5 cm in size, but had no benefit in patients with 1 positive node or 2 positive nodes with tumor ≤2 cm. McBride, *et al* \[[@R37]\] also observed that the benefit of PMRT on local control was highly dependent on the era of treatment: PMRT reduced the risk of 5-year LRR in patients treated in an early era (1978--1998), but not in those treated in a later era (2000--2007), when the use of sentinel lymph node surgery, taxane chemotherapy, and aromatase inhibitors was routine. Taken together, we may reconsider the benefit of PMRT on OS among N1 breast cancer patients. Further randomized controlled studies addressing this issue are warranted.

Limitations {#s3_5}
-----------

In this observational study, we were not able to retrieve information such as multifocality, EIC, HER2 status, BRCA status, body-mass index, detailed chemotherapy, endocrine therapy, targeted therapy and cancer-specific survival (CSS) from the NCDB. Thus, the selection biases cannot be completely diminished, although we used propensity score analysis. 1) BRCA mutation-positive patients would tend to receive mastectomy. However, a recent study showed that the 10-year OS is similar between patients with or without the BRCA mutation \[[@R38]\]. In addition, HER2 status is not expected to be associated with the choice of surgery (mastectomy *vs*. BCS). Therefore, the failure to match for BRCA status or HER2 status would not have a significant impact on our analysis. 2) Patients with positive margins, who were converted to mastectomy from BCS, were likely associated with multifocal DCIS or EIC. Hence, the inability to match for multifocality is a major limitation of this study. 3). Lack of information of BCSS in the NCDB is another limitation of our study. However, a summary of previous studies \[[@R8], [@R9], [@R12], [@R20]\] showed that the survival benefit of BCS+RT (over mastectomy) on BCSS was similar to that of OS (Table [3](#T3){ref-type="table"}). Thus, we think that OS is also a valid endpoint for our study. 4) We are not able to ensure that the chemotherapy treatments were completely comparable between groups.

MATERIALS AND METHODS {#s4}
=====================

Data collection {#s4_1}
---------------

We searched the NCDB registry data between 2004 and 2011 and identified female patients with a T1--2N0--3M0 infiltrating duct breast carcinoma diagnosis. The following information was collected: facility type (community cancer program, comprehensive community cancer program, academic/research program, other program); primary payer (not insured, private insurance, Medicaid, Medicare, other government); city type (metropolitan, urban, rural); distance to hospital; median income of the state/area (2008--2012) where the patient lived; the percentage of population without a high school degree of the state/area where the patient lived; age; race; T stage; N stage; AJCC stage; laterality (left or right breast); estrogen receptor (ER) status; progesterone receptor (PR) status; grade; surgery of primary site; radiation; survival (months); vital status; primary site (LIQ, lower-inner quadrant; LOQ, lower-outer quadrant; UIQ, Upper-inner quadrant; UOQ, Upper-outer quadrant; nipple; others); days of inpatient stay; Charlson-Deyo (CD) score; lymphovascular invasion status; chemotherapy(administered as first course treatment); and hormonal therapy (administered as first course treatment). For the breast surgery code, we used the NAACCR item \#1290 coding rules (breast, C50.0--C50.9,<http://ncdbpuf.facs.org/?q=content/breast>). We defined codes 20--24 as BCS and codes 41 and 51 as mastectomy.

The data within the NCDB are rendered anonymous; therefore, the study was exempt from the Johns Hopkins Medicine Institutional Review Board review, and no consent was required.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

We had rigorous inclusion and exclusion criteria for patient selection. All of the included patients met the following inclusion and exclusion criteria.

Inclusion criteria {#s4_3}
------------------

1.  Female, T1--2N0--3M0 breast cancer patients, diagnosis after 2004.

2.  Infiltrating ductal breast carcinoma (histology coding 8500) with confirmed pathology diagnosis.

3.  Patients with grossly and microscopically negative margins.

Exclusion criteria {#s4_4}
------------------

1.  Patients with previous diagnosis of breast cancer or any malignant tumors (In this study, patients with the sequence number code of 00 or 01 were included)

2.  Patients with pure DCIS or stage 0 disease.

3.  Patients with unknown information for any of the included variables, except for lymphovascular invasion.

4.  Patients with bilateral breast cancers.

5.  Patients with a pathological tumor size larger than 5 cm.

6.  Patients with a history of RT.

7.  Patients who did not receive RT after BCS.

8.  Patients who received hormone therapy for ER- and PR- disease.

9.  Patients who did not receive hormone therapy for ER+ or PR+ disease.

Statistical analyses {#s4_5}
--------------------

The chi-square test was used to compare the demographic and clinicopathological features of patients among three groups: the BCS + RT group; the mastectomy-alone group; and the mastectomy + RT group. Kaplan-Meier survival analysis and an unadjusted Cox proportional hazards model were used to compare the overall survival (OS) of patients who received the different treatments, as a univariate approach. Significant factors revealed by univariate analysis were incorporated into multivariate analysis (adjusted Cox proportional hazards model) and the model was used through out the entire study. In subgroup analysis, we planned to assess the effect of surgery type on OS in patients stratified by N-stages, comorbidities and ages. The variables that were used for stratification were not included in the multivariate model during subgroup analysis.

Propensity analysis was used to compare treatment groups within strata to minimize selection bias or a lack of covariate balance. We considered that age, facility type, primary payer, primary sites, income, urban type, education, distance to hospital, CD score, race, tumor grade, ER, PR, T stage and N stage were all potential determinants for the choice of surgery. Thus, all of these variables were included as conditioning variables in a logistic model, with surgery type (BCS+RT *vs*. mastectomy alone or RT) as the outcome variable. The propensity score was then calculated as the probability of receiving a mastectomy (alone or with RT) for each individual. We stratified the patients into quintiles, in which patients had a similar likelihood of having received a given treatment. Using the Cox model, we estimated the effect of different treatments (BCS+RT, mastectomy alone or mastectomy+RT) on OS, with the baseline survival function varied across strata by including quintiles of the propensity scores as stratification variables.

All *P* values are two sided. *P* values \<0.05 were considered statistically significant. A survival difference larger than 5% was considered clinically significant. Statistical analyses were performed using Stata/MP, version 13.0 (StataCorp LP, College Station, TX, USA).

CONCLUSIONS {#s5}
===========

This analysis of a large national cohort of patients demonstrates that BCS+RT provides a superior OS to mastectomy (alone or with RT) in N0 and N1 patients, regardless of comorbid conditions. In N2--3 patients, the survival benefit of BCS+RT (*vs*. mastectomy+RT) was eliminated when patients with comorbid conditions were excluded. Among patients aged 50 or younger, the BCS+RT OS is equivalent to mastectomy (alone or with RT). Because mastectomy is significantly more invasive than BCS+RT, we recommend greater efforts at educating patients to undergo BCS+RT rather than mastectomy in our routine practice, particularly for low-risk N0/N1 women.

SUPPLEMENTARY TABLES {#s6}
====================
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